Related Experiment Videos

Signaling through Raf-1 in the neovasculature and target validation by nanoparticles

Kishore K Wary1

  • 1Center for Extracellular Matrix Biology, Institute of Biosciences and Technology, Texas A&M University System-Health Science Center, 2121 W. Holcombe Blvd, Houston, TX-77030, USA. kwary@ibt.tamushsc.edu

Molecular Cancer
|September 4, 2003
PubMed

Insights

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) activate Raf-1 kinase, protecting endothelial cells from apoptosis. This finding supports nanoparticle delivery of anti-angiogenic molecules for tumor regression.

Area of Science:

  • Molecular biology
  • Cell biology
  • Cancer research

Background:

  • Tumor neovasculature presents unique molecular markers.
  • Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) play roles in angiogenesis.
  • Raf-1 kinase is a key signaling molecule in cellular pathways.

Purpose of the Study:

  • To investigate the activation pathways of Raf-1 kinase by VEGF and bFGF.
  • To determine the role of Raf-1 kinase phosphorylation in endothelial cell survival.
  • To explore the potential of targeting tumor neovasculature for cancer therapy.

Main Methods:

  • Experimental neovasculature system used to study kinase activation.
  • Analysis of p21-activated protein kinase-1 (PAK-1) and Src kinase activation.
  • Phosphorylation site identification on Raf-1 kinase.

Main Results:

  • VEGF activates Src kinase, while bFGF activates PAK-1.
  • PAK-1 and Src kinases phosphorylate specific sites on Raf-1 kinase.
  • Phosphorylation of Raf-1 protects endothelial cells from apoptosis.

Conclusions:

  • VEGF and bFGF signaling pathways converge on Raf-1 kinase activation.
  • Targeting tumor-specific neovasculature with nanoparticles offers a therapeutic strategy.
  • Nanoparticle-mediated delivery of anti-angiogenic agents can induce tumor regression.

Related Concept Videos